Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Equity Average (2016 - 2025)

United Therapeutics (UTHR) has disclosed Equity Average for 16 consecutive years, with $6.8 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 9.1% to $6.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 billion through Dec 2025, up 9.1% year-over-year, with the annual reading at $6.8 billion for FY2025, 8.94% up from the prior year.
  • Equity Average hit $6.8 billion in Q4 2025 for United Therapeutics, down from $6.9 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $7.0 billion in Q2 2025 to a low of $3.4 billion in Q1 2021.
  • Historically, Equity Average has averaged $5.2 billion across 5 years, with a median of $5.4 billion in 2023.
  • Biggest five-year swings in Equity Average: increased 4.76% in 2024 and later grew 26.69% in 2025.
  • Year by year, Equity Average stood at $3.9 billion in 2021, then increased by 20.16% to $4.7 billion in 2022, then increased by 24.98% to $5.8 billion in 2023, then rose by 7.25% to $6.3 billion in 2024, then grew by 9.1% to $6.8 billion in 2025.
  • Business Quant data shows Equity Average for UTHR at $6.8 billion in Q4 2025, $6.9 billion in Q3 2025, and $7.0 billion in Q2 2025.